BMAL1 and Parkinson disease: In the 1‐methyl‐4‐phenyl‐1,2,4,5‐tetrahydropyridine‐induced PD mouse model, inactivation of Bmal1 can lead to distinct motor dysfunction, dopaminergic neuronal injury in the substantia nigra pars compacta, deficiency in dopamine transmitters, and aggravation of the neuroinflammatory response, suggesting that Bmal1 may exert a beneficial effect on survival of dopaminergic neurons by regulating the microglia‐mediated neuroinflammation response (Liu et al., 2020).